Hypercalciuria
Conditions
Interventions
This is an observational and temporal or cross sectional study, where blood and urinary samples were collected from 70 children and adolescents followed at the Pediatric Nephrology Unit of the Medical
Other
Sponsors
Faculdade de Medicina da Universidade Federal de Minas Gerais
Children's Mercy Hospital
Eligibility
Age
3 Years to 21 Years
Inclusion criteria
Inclusion criteria: Pediatric patients; both genders; with diagnosis of Idiopathic Hypercalciuria; age between 3 and 21 years; with diurnal and nocturnal urinary sphincter control.
Exclusion criteria
Exclusion criteria: Pregnant adolescents; patients with nephrocalcinosis; chronic immobilization; hypercalcemia; history of malignancy; excessive intake of calcium and vitamin D; hyperuricemia; prolonged corticoterapia; renal tubular diseases; use of drugs that interfere with calcium metabolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1 It is expected that levels of fibroblast growth factor are altered in patients diagnosed with idiopathic hypercalciuria, as verified by their plasma dosage by the ELISA method, which will increase their baseline by twice. These levels were measured before treatment in 24 patients and after treatment in 34 patients. ;Found outcome 1 Fibroblast growth factor levels were found to be significantly altered in patients with Idiopathic Hypercalciuria. Patients with pre-treatment values had FGF23 of 73.0 (32.0-190.0) and those patients with values dosed after treatment of 50.0 (7.0-368.0) p = 0.02 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected. | — |
Countries
Brazil
Contacts
Public ContactMaria Goretti Penido
Universidade Federal de Minas Gerais
Outcome results
None listed